Abstract
Introduction Dengue, a viral infection highly prevalent in tropical regions, exhibits local variations in risk that are influenced by a combination of climatic, socioeconomic, and environmental factors. The disease is caused by four distinct yet closely related serotypes of the dengue virus: DENV-1, DENV-2, DENV-3, and DENV-4.
Objectives The objective of this study is to identify the different serotypes of dengue virus responsible for the 2022 outbreak in Nepal, where dengue has been prevalent since 2006 but with limited availability of molecular information on the serotypes.
Methodology Serum samples from suspected dengue patients visiting Dhulikhel Hospital were analyzed using Dengue Ag and IgM/IgG Ab Kit test, for the presence of IgG/IgM antibodies or NS1 Ag. The positive samples were stored at -80 °C, and 89 samples were selected for further analysis. RNA was extracted from those positive samples using the Zymo Quick RNA Viral Kit, and RT-PCR was performed using the Sacace Dengue Real Genotype qPCR kit to identify the dengue virus serotypes present.
Results The study included 89 samples, of which a higher percentage of sero-positivity was observed in females (52%) compared to males. Positive cases were distributed in 14 different districts, with the highest percentage (58.4%) in Kavre. Molecular investigation, of 53 out of 89 serologically positive samples, by qPCR revealed that DENV1 was the predominant serotype, followed by DEN3 (24.5%) and DENV2 (16.9%). DENV4 was not detected in any of the samples. The average Ct value of all serotypes was 17.6, with DENV3 having the lowest Ct value of 16.6, indicating a high viremia.
Conclusion Our study, although limited in its coverage of Nepal, has provided molecular information on the serotypes responsible for the 2022 dengue outbreak. The high prevalence of DENV1 was observed, while prevalence of DENV3 was accompanied by high viral load. This information provided valuable insight into the circulating serotypes of the virus in the region.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded from Provincial Health Research Grant 2079/80 provide by Nepal Health Research Council (NHRC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Review Board of Nepal Health Research Council (NHRC) gave ethical approval for this work. [107 - 2023] Ethical Review Board (IRC-KUSMS) of Kathmandu University School of Medical Sciences gave ethical approval for this work. [17/23]
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
